The Tuberculosis (TB) vaccine, known as Bacillus Calmette-Guérin (BCG), is a live attenuated vaccine derived from a strain of Mycobacterium bovis. BCG vaccination is primarily administered in regions with a high prevalence of TB and is often given to infants. The BCG vaccine provides variable protection against severe forms of childhood TB, particularly meningitis and disseminated disease. However, its efficacy against pulmonary TB, the most common form, varies, and it does not prevent the primary infection. Diagnosing and treating active TB cases remain the primary strategies for TB control. BCG vaccination is not routinely recommended in countries with a low TB incidence but may be administered to individuals at high risk, such as healthcare workers or those in close contact with TB patients. Research continues to explore new TB vaccines that offer enhanced protection, especially against pulmonary TB. Global efforts focus on improving diagnostics, treatment, and vaccine strategies to achieve the World Health Organization's goal of eliminating TB as a public health threat by 2035.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States